Preference of Tegaserod vs. PEG 3350 in Patients With Constipation

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

To determine whether female patients have a preference for tegaserod of PEG 3350 relative to dosage form, convenience, ease of administration and taste

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Treatments: Polyethylene glycol 3350; Tegaserod

Criteria

Inclusion Criteria:

• Females aged 18 to 64 years of age

• Patients with constipation as defined by the Rome II criteria

Exclusion Criteria:

• Patients who have been previously been treated with tegaserod and/or PEG 3350

• Evidence of cathartic colon or a history of laxative abuse or laxative dependence

• History of fecal impaction which necessitated surgical intervention

• Patients with clinically significant abnormal TSH levels at screening

• Women who are pregnant or breast feeding

Other protocol-defined inclusion/exclusion criteria may apply